Bristol-Myers Squibb | BMY - Interest Expense On Debt


Bristol-Myers Squibb reported $403M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Abbott USD 297M 2M Sep/2026
ALKERMES USD 27.55M 1.63M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 316M 201.3M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 186M 10M Jun/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 13.94M 2.52M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Sanofi EUR -25M 99.78M Dec/2025
United Therapeutics USD 2.9M 0 Sep/2026
Zoetis USD 62M 1000K Sep/2026